BNP Paribas Asset Management
RCUS icon

BNP Paribas Asset Management’s Arcus Biosciences RCUS Stock Holding History

BNP Paribas Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.8M Sell
1,419,533
-235,221
-14% -$5.81M 0.04% 378
2026
Q1 		$35.7M Sell
1,654,754
-32,620
-2% -$704K 0.04% 405
2025
Q4 		$40.2M Buy
1,687,374
+267,389
+19% +$5.46M 0.05% 355
2025
Q3 		$19.3M Buy
1,419,985
+24,259
+2% +$252K 0.05% 357
2025
Q2 		$11.4M Sell
1,395,726
-232,293
-14% -$1.98M 0.03% 433
2025
Q1 		$12.8M Buy
1,628,019
+106,235
+7% +$1.23M 0.03% 407
2024
Q4 		$22.7M Buy
1,521,784
+590,736
+63% +$9.65M 0.06% 310
2024
Q3 		$14.2M Buy
931,048
+186,750
+25% +$2.94M 0.04% 374
2024
Q2 		$11.3M Buy
744,298
+59,273
+9% +$957K 0.03% 404
2024
Q1 		$12.9M Buy
685,025
+145,298
+27% +$2.51M 0.03% 390
2023
Q4 		$10.3M Buy
539,727
+22,863
+4% +$365K 0.03% 417
2023
Q3 		$9.28M Sell
516,864
-94,308
-15% -$1.89M 0.03% 419
2023
Q2 		$12.4M Sell
611,172
-163,620
-21% -$3.12M 0.04% 364
2023
Q1 		$14.1M Buy
774,792
+9,242
+1% +$177K 0.05% 362
2022
Q4 		$15.8M Buy
765,550
+142,986
+23% +$3.93M 0.06% 348
2022
Q3 		$16.3M Buy
622,564
+63,962
+11% +$1.69M 0.06% 323
2022
Q2 		$14.2M Sell
558,602
-238,489
-30% -$5.84M 0.05% 341
2022
Q1 		$25.2M Sell
797,091
-64,203
-7% -$2.15M 0.09% 267
2021
Q4 		$34.9M Buy
861,294
+76,188
+10% +$2.96M 0.12% 211
2021
Q3 		$27.4M Buy
785,106
+473,310
+152% +$14.7M 0.1% 234
2021
Q2 		$8.56M Buy
+311,796
New +$8.91M 0.03% 460

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BNP Paribas Asset Management's RCUS Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Arcus Biosciences (RCUS) stake by 14% in Q2 2026, selling an estimated $5.81M and leaving 1,419,533 shares worth $43.8M. The position accounts for 0.04% of the portfolio, ranked #378.

BNP Paribas Asset Management first reported a position in RCUS in Q2 2021 and has held it in 21 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • BNP Paribas Asset Management held 1,419,533 shares of Arcus Biosciences worth $43.8M as of Q2 2026.
  • BNP Paribas Asset Management sold 235,221 Arcus Biosciences shares in Q2 2026, an estimated $5.81M.
  • Arcus Biosciences made up 0.04% of BNP Paribas Asset Management's portfolio in Q2 2026, its #378 holding.
  • BNP Paribas Asset Management first reported a position in Arcus Biosciences in Q2 2021 and has held it in 21 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.